Acerus Pharmaceuticals Stock EBITDA
ASPCFDelisted Stock | USD 0.22 0.00 0.00% |
Acerus Pharmaceuticals fundamentals help investors to digest information that contributes to Acerus Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acerus OTC Stock. The fundamental analysis module provides a way to measure Acerus Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acerus Pharmaceuticals otc stock.
Acerus |
Acerus Pharmaceuticals OTC Stock EBITDA Analysis
Acerus Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Acerus Pharmaceuticals EBITDA | (31.5 M) |
Most of Acerus Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acerus Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Acerus Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (31.5 Million). This is 103.59% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The ebitda for all United States stocks is 100.81% higher than that of the company.
Acerus EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acerus Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Acerus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acerus Pharmaceuticals by comparing valuation metrics of similar companies.Acerus Pharmaceuticals is currently under evaluation in ebitda category among related companies.
Acerus Fundamentals
Return On Equity | -22.42 | |||
Return On Asset | -0.54 | |||
Operating Margin | (8.41) % | |||
Current Valuation | 49.66 M | |||
Shares Outstanding | 7.71 M | |||
Shares Owned By Insiders | 91.41 % | |||
Price To Book | 20.08 X | |||
Price To Sales | 2.16 X | |||
Revenue | (4.13 M) | |||
Gross Profit | 1 M | |||
EBITDA | (31.5 M) | |||
Net Income | (33.82 M) | |||
Cash And Equivalents | 1.29 M | |||
Cash Per Share | 0.17 X | |||
Total Debt | 21.14 M | |||
Debt To Equity | 2.61 % | |||
Current Ratio | 0.37 X | |||
Book Value Per Share | (1.80) X | |||
Cash Flow From Operations | (23.52 M) | |||
Earnings Per Share | (3.63) X | |||
Number Of Employees | 14 | |||
Beta | 1.35 | |||
Market Capitalization | 2.09 M | |||
Total Asset | 9.65 M | |||
Z Score | -9.9 | |||
Net Asset | 9.65 M |
About Acerus Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acerus Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acerus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acerus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Acerus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acerus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acerus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Acerus OTC Stock
0.84 | TEVA | Teva Pharmaceutical | PairCorr |
0.48 | TPDDF | Talon Energy | PairCorr |
0.47 | MKKGY | Merck KGaA ADR | PairCorr |
0.47 | MKGAF | MERCK Kommanditgesells | PairCorr |
0.45 | LRDG | Lord Global Corp | PairCorr |
The ability to find closely correlated positions to Acerus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acerus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acerus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acerus Pharmaceuticals to buy it.
The correlation of Acerus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acerus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acerus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acerus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Acerus Pharmaceuticals information on this page should be used as a complementary analysis to other Acerus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Acerus OTC Stock
If you are still planning to invest in Acerus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acerus Pharmaceuticals' history and understand the potential risks before investing.
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |